Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca stroke drug fails study
The phase III study of NXY-059 failed to meet the study goal and did not improve stroke related disability. Additionally treatment with NXY-059 did not result in a
The phase III study of NXY-059 failed to meet the study goal and did not improve stroke related disability. Additionally treatment with NXY-059 did not result in a
The companies were advised that the 30 day waiting period under the Hart-Scott-Rodino act was terminated early by the Federal Trade Commission. In the agreement, Eisai obtained exclusive
Tyzeka is a product of a commercialization agreement between Novartis and Idenix established in May 2003. Tyzeka rapidly and profoundly suppresses the hepatitis B virus in adult patients
Zostavax was approved by the FDA on May 25 for the prevention of shingles in individuals 60 years of age and older and is given by a single
Gemzar is an approved chemotherapy, marketed for use in pancreatic, ovarian, lung and breast cancer. Key objectives for the phase I portion of the study will be to
One of the significant risks associated with heart surgery is cognitive impairment. This can be identified a few days or weeks following the procedures and in many cases
The clinical trial will test the vaccine in a dose-escalation trial involving 24 healthy volunteers. The main parameters under examination will be safety, tolerability and immunogenicity. “The start
The termination of the agreement with PDI will be effective from December 1, 2006. The contract, which represents approximately $18 million to $20 million in revenue on an
The study, designed to assess the safety of 1207, will enroll 24 adult healthy male volunteers in Australia. In addition to safety data, the study will measure sensory
A steering committee has put a phase IIB/III study of desmoteplase on hold until further data have been analyzed. The study is evaluating the effects of desmoteplase in